Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2018-07
-
To investigate the potential molecular mechanism
2022-02-28

To investigate the potential molecular mechanism of FXR-mediated regulation of liver cancer cell proliferation, gene expression profiles were determined using Agilent arrays in SK-Hep-1-FXR and NC after treatment with the FXR agonist GW4064. The results indicate that mTOR and S6k are involved in div
-
There are several basic science studies that aim to investig
2022-02-28

There are several basic science studies that aim to investigate potential mechanisms behind the reduced incidence of MI in factor Xa inhibitor treated patients. Perzborn et al. reported that in-vitro addition of rivaroxaban reduced tissue-factor induced platelet aggregation (Perzborn, Heitmeier, & L
-
Treatment with histamine had no effect
2022-02-28

Treatment with histamine had no effect on histamine H1 receptor expression in HepG2 enfuvirtide (Fig. 1), while knockdown of histamine H1 receptor expression prevented histamine from repressing apo A-I gene expression (Fig. 2). Overexpression of the histamine H1 receptor regulated apo A-I promoter
-
Vatalanib mg In conclusion re evaluation of HER
2022-02-28

In conclusion, re-evaluation of HER2 status is necessary to determine the appropriate use of anti-HER2–targeted therapy beyond disease progression. EGFR and c-met amplification, as well as PIK3CA mutation, are rarely associated with acquired resistance. Our results highlight the importance of formal
-
Currently the computational chemical biology has been
2022-02-28

Currently, the computational chemical biology has been applied in hepatitis B antiviral drug discovery research [18]. Tan et al. explored oxime ethers as HBV inhibitors by docking and screening [19]. Allen et al. clarified the resistance of HBV to the nucleoside drug lamivudine [20]. The results sug
-
Urinary As species monomethylated MMAV percentage
2022-02-28

Urinary As species monomethylated (MMAV) percentage might increase and As species dimethylated (DMAV) percentage might decrease with increasing As exposure dosage (Lindberg et al., 2008). The limited methylation capacity associated with increased of As exposure dosage might probably explained throug
-
Whereas binding of activated RhoA to the
2022-02-28

Whereas binding of activated RhoA to the PH domains of the RhoGEFs is proposed to mediate positive feedback regulation (Chen et al., 2010b, Medina et al., 2013), the sequestration of p190RhoGEF by activated Rac1 reveals a novel putative physiological role, that is to utilize Rac1 to directly drive r
-
Introduction The onset of uterine labor is the culmination
2022-02-26

Introduction The onset of uterine labor is the culmination of a gradual uterine activation wherein physiological inflammation induces a common prolabor pathway characterized by increased myometrial contractility, weakening of fetal membrane integrity, and cervical ripening. Pathological proinflamma
-
br GR Is a Transcriptional Activator How GR activates
2022-02-26

GR Is a Transcriptional Activator How GR activates some genes while repressing others remains unsettled after decades of study. While significant controversy exists regarding GR-mediated repression, a consensus model for transcriptional activation has emerged: GR activates transcription through s
-
br Conflict of interest statement
2022-02-26

Conflict of interest statement Acknowledgements This work was supported by the National Health and Medical Research Council of Australia (NHMRC) (project grants [1061044], [1065410] and [1126857], and NHMRC program grant [1055134]); P.M.S. and A.C. are NHMRC Principal and Senior Principal Rese
-
Chitosan CS a deacetylated derivative
2022-02-26

Chitosan (CS), a deacetylated derivative of chitin, was chosen in this study due to its unique biological characteristics including biodegradability, biocompatibility, non-toxicity, and antimicrobial properties (Klossner, Queen, Coughlin, & Krause, 2008; Kong, Chen, Xing, & Park, 2010; Ravi Kumar, 2
-
In addition at the spinal level results from colocalization
2022-02-26

In addition, at the spinal level, results from colocalization experiments demonstrate that GABA-C receptors are present in the substantia gelatinosa and that they are presynaptically located. Neurons located in the substantia gelatinosa are differentially activated by afferent noxious and non-noxiou
-
br Fenton reaction based nanomaterials for ferroptosis
2022-02-26

Fenton reaction-based nanomaterials for ferroptosis In Fenton reaction, H2O2 is converted by Fe2+ or Fe3+ to highly oxidative ROS (Eqs. (1) and (2)), which is commonly used to catalyze the degradation of refractory organics [34]. Since the tumor microenvironment is characterized by low acidity an
-
In non Hodgkin lymphoma the catalytic SET domain of
2022-02-26

In non-Hodgkin lymphoma the catalytic SET domain of the histone methyltransferase EZH2 is subject to recurrent heterozygous missense mutations . These alterations have been observed in ∼20% of patients with diffuse large B cell lymphoma (DLBCL) and ∼10% of patients with follicular lymphoma (FL). The
-
br Results br Discussion Previous studies
2022-02-26

Results Discussion Previous studies have shown that all the components of ET system are expressed by various neuronal and non-neuronal structures throughout the CNS (McCumber et al., 1990; Giaid et al., 1991). In effect, endothelin-converting enzyme activity, mRNA, ET-1 and ET-3 immunoreactivi
15131 records 505/1009 page Previous Next First page 上5页 501502503504505 下5页 Last page